Alzheimer's Clinical Trials Consortium (ACTC) Clinical Trials is sponsored by National Institutes of Health. Alzheimer's Clinical Trials Consortium (ACTC) Clinical Trials is a forecasted funding opportunity on Grants.gov from National Institutes of Health. Fiscal Year: 2026. Assistance Listing Number(s): 93.866. <p><span style="color: rgb(51, 51, 51);">The National Institute on Aging (NIA) intends to publish a Notice of Funding Opportunity (NOFO) to invite applications to develop and implement multi-site Phase Ib to III clinical trials of promising pharmacological and non-pharmacological interventions that may prevent, delay, or treat the symptoms of Alzheimer's disease (AD) and AD-related dementias (ADRD) using the Alzheimer's disease Clinical Trials Consortium (ACTC) trial coordination and management ...

NOT-AG-24-084: Notice of Intent to Publish a Notice of Funding Opportunity for Alzheimer's Clinical Trials Consortium (ACTC) Clinical Trials (R01 Clinical Trial Required) is sponsored by National Institute on Aging (NIA). Intends to publish a funding opportunity for multi-site clinical trials of interventions for Alzheimer's disease using the ACTC infrastructure.

The NIAID Investigator-Initiated Clinical Trials program from the National Institute of Allergy and Infectious Diseases provides funding for clinical research on infectious diseases, allergic diseases, and immunological conditions. NIAID supports a wide range of clinical trial designs, from early-phase feasibility studies to large pivotal trials, enabling investigators to test novel treatments, vaccines, diagnostics, and prevention strategies. Eligible applicants include nonprofits, for-profit organizations, and other entities conducting biomedical research in areas aligned with NIAID's mission. Award amounts vary by the scope and phase of the proposed clinical trial.